tisagenlecleucel
Next-Gen Cell Therapies Bedeviled by Regulatory Murkiness on Product Characterization, Manufacturing
Premium
At a recent Friends of Cancer Research meeting, drugmakers and regulators said communication has improved on cell therapy development programs but acknowledged persistent challenges.
Investigators in Shanghai saw a 99 percent complete response rate among advanced B-ALL patients receiving two populations of autologous CAR T cells at once.
AmplifyBio Hoping to Lure Cell and Gene Therapy Clients With Newly Acquired Characterization Tech
Premium
The CRO has acquired a suite of assets from PACT Pharma that it hopes will bolster its product characterization services for pharma partners developing cell and gene therapies.
By tracking blood phosphate concentrations, doctors may be able to mitigate immune effector cell neurotoxicity syndrome, according to a newly published study.
European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients
The autologous CAR T-cell therapy is now available in Europe as a fourth-line option for relapsed or refractory follicular lymphoma patients.